NOVAVAX INC (NVAX) Latest Company News

Oct 19, 2026, 22:46 UTC
NOVAVAX INC shares closed at $10.82, down 3.91% from the prior session's close.
Source:
- zacks.com
Oct 16, 2026, 21:24 UTC
NOVAVAX INC shareholder Shah Capital Management said it would step back from its activist role at NOVAVAX INC.
Source:
- reuters.com
Oct 13, 2026, 22:45 UTC
NOVAVAX INC shares closed at $12.82, up 1.26% from the previous trading day.
Source:
- zacks.com
Oct 12, 2026, 16:16 UTC
Shares of Moderna, Inc., BioNTech SE and NOVAVAX INC rallied following reports of a planned U.S.-led initiative to accelerate personalized cancer vaccines and expand research funding.
Source:
- zacks.com
Oct 6, 2026, 14:18 UTC
Novavax Inc. shares pulled back on Tuesday after surging more than 20% on Monday amid a rally in vaccine stocks.
Source:
- benzinga.com
Oct 5, 2026, 20:32 UTC
Novavax shares posted their biggest gain as investors reacted to a suspected plague death at a Siberian research institute in Russia.
Source:
- benzinga.com
- zacks.com
Sep 28, 2026, 22:45 UTC
Novavax (NVAX) shares rose 1.53% to close at $10.79 while the broader market declined.
Source:
- zacks.com
Sep 18, 2026, 22:45 UTC
Novavax (NVAX) shares closed at $10.11, up 1.1% from the previous trading day.
Source:
- zacks.com
Sep 18, 2026, 08:46 UTC
Novavax (NVAX) shares jumped 7.0% in the prior trading session on above-average trading volume.
Source:
- zacks.com
Aug 28, 2026, 12:30 UTC
Novavax's partners received approvals for the XFG-adapted Nuvaxovid COVID-19 vaccine formulation for the 2026-2027 vaccination season in the U.S., EU, and Japan.
Source:
- prnewswire.com
- benzinga.com
Aug 6, 2026, 12:00 UTC
Novavax reported total revenue of $57 million for the second quarter of 2026 and raised its full-year 2026 revenue framework and improved GAAP combined R&D and SG&A expense guidance by $10 million at the midpoint.
Source:
Jul 19, 2026, 15:52 UTC
Jianyi Biotechnology (a subsidiary of Shengde Group) signed a formal cooperation agreement with Polish CDMO company Mabion S.A. to jointly develop antibody-drug conjugates (ADCs) and target the European CDMO market.
Source:
- money.udn.com

NVAX

NOVAVAX INC shares closed at $10.82, down 3.91% from the prior session's close.

NOVAVAX INC shareholder Shah Capital Management said it would step back from its activist role at NOVAVAX INC.

NOVAVAX INC shares closed at $12.82, up 1.26% from the previous trading day.

Shares of Moderna, Inc., BioNTech SE and NOVAVAX INC rallied following reports of a planned U.S.-led initiative to accelerate personalized cancer vaccines and expand research funding.

Novavax Inc. shares pulled back on Tuesday after surging more than 20% on Monday amid a rally in vaccine stocks.

Novavax shares posted their biggest gain as investors reacted to a suspected plague death at a Siberian research institute in Russia.

Novavax (NVAX) shares rose 1.53% to close at $10.79 while the broader market declined.

Novavax (NVAX) shares closed at $10.11, up 1.1% from the previous trading day.

Novavax (NVAX) shares jumped 7.0% in the prior trading session on above-average trading volume.

Novavax's partners received approvals for the XFG-adapted Nuvaxovid COVID-19 vaccine formulation for the 2026-2027 vaccination season in the U.S., EU, and Japan.

Novavax reported total revenue of $57 million for the second quarter of 2026 and raised its full-year 2026 revenue framework and improved GAAP combined R&D and SG&A expense guidance by $10 million at the midpoint.

Jianyi Biotechnology (a subsidiary of Shengde Group) signed a formal cooperation agreement with Polish CDMO company Mabion S.A. to jointly develop antibody-drug conjugates (ADCs) and target the European CDMO market.